治疗肺动脉高压的新型激活素信号抑制剂—sotatercept
A novel activin signaling inhibitor for the treatment of pulmonary arterial hypertension:sotatercept
李小宝 1张美娟 2董瑞华2
作者信息
- 1. 北京市丰台区右安门社区卫生服务中心,北京 100069
- 2. 首都医科大学附属北京友谊医院 研究型病房,北京 100050
- 折叠
摘要
sotatercept(MK-7962,ACE-011)是一种新型激活素受体ⅡA-Fc型(ActRⅡA-Fc)融合蛋白,可以通过抑制激活素的信号传导,靶向逆转肺动脉高压(PAH)导致的肺血管重构.Ⅱ、Ⅲ期临床试验结果表明,sotatercept对PAH具有明确疗效,可以改善PAH患者的运动能力,且安全性和耐受性良好,FDA批准用于治疗PAH.本文针对sotatercept的作用机制、药动学、临床疗效、安全性、用法用量、药物相互作用及药物研究进展等进行概述.
Abstract
Sotatercept(MK-7962,ACE-011)is a novel fusion protein of the activin receptor ⅡA-FC(ActRⅡA-Fc)that targets and reverses pulmonary vascular remodeling caused by pulmonary arterial hypertension(PAH)by inhibiting activin signaling.Phase Ⅱ and Ⅲ clinical trials have demonstrated that sotatercept has a significant therapeutic effect on PAH,enhances the exercise capacity of patients with PAH,and exhibits good safety and tolerability,leading to its FDA approval for PAH treatment.This article offers an overview of the mechanism of action,pharmacokinetics,clinical efficacy,safety profile,dosage,drug interactions,and the latest research developments of sotatercept.
关键词
sotatercept/激活素信号抑制剂/肺动脉高压Key words
sotatercept/activin signaling inhibitor/pulmonary arterial hypertension引用本文复制引用
出版年
2024
NETL
NSTL
万方数据